Rituximab for Progressive Interstitial Lung Disease and Vasculopathy in Mixed Connective Tissue Disease: A Case Report
Keywords:
Mixed Connective Tissue Disease, Interstitial Lung Disease, Vasculopathy, Rituximab Therapy, Case ReportAbstract
This case highlights the successful use of Rituximab in a patient with MCTD presenting with progressive ILD and vasculopathy, unresponsive to standard therapies. Symptoms included fever, myalgia, Raynaud’s phenomenon, alopecia, skin rash, digital gangrene, dyspnoea, and digital ulcers. Clinical findings showed NSIP, positive autoimmune markers, and moderate restrictive lung pattern. Diagnosed with MCTD with myositis, NSIP, and vasculopathy. Treated initially with steroids and immunosuppressants; Rituximab was added during disease progression, leading to marked clinical improvement. Rituximab may be effective in refractory MCTD with progressive ILD and vasculopathy, supporting its role in individualized treatment strategies.
Downloads
Metrics
References
Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): A double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11(1):45–54. doi:10.1016/S2213-2600(22)00359-9.
Seedat UF, Christian B, Boshoff PE, Gaylard P, Schleicher GK. Rituximab therapy in severe connective tissue disease-associated interstitial lung disease: A retrospective single-centre observational study. Afr J Thoracic Crit Care Med. 2024;30(3):e1431. doi:10.7196/AJTCCM.2024.v30i3.1431.samajournals.co.za+1Journals.co.za+1.
Zhao Y, Gao Y, Petnak T, et al. Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: A systematic review and meta-analysis. Respir Res. 2022;23:164. doi:10.1186/s12931-022-02082-x.
Pascual M, Narváez J, Albert Espi G, et al. Rituximab in refractory mixed connective tissue disease: An observational study. ACR Meeting Abstracts. 2015;277. Available from: https://acrabstracts.org/abstract/rituximab-in-refractory-mixed-connective-tissue-disease-an-observational-study/.
Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): A double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11(1):45–54. doi:10.1016/S2213-2600(22)00359-9.
Adams H, van de Garde EMW, Vugts DJ, et al. [89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: A phase 2 trial. Eur J Nucl Med Mol Imaging. 2023;50(7):1929–1939. doi:10.1007/s00259-023-06143-1.
Wang Y, Li L. Rituximab for connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Int J Rheum Dis. 2023;26(2):225–235. doi:10.1111/1756-185X.14495.
Mankikian J, Caille A, Reynaud-Gaubert M, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): A double-blind, randomised, placebo-controlled trial. Eur Respir J. 2023;61(6):2202071. doi:10.1183/13993003.02071-2022.
Boppana TK, Mittal S, Madan K, et al. Rituximab for rheumatoid arthritis-related interstitial lung disease: A systematic review and meta-analysis. Arch Rheumatol. 2024;39(2):317–329. doi:10.46497/ArchRheumatol.2024.10199.
Vacchi C, Manfredi A, Cassone G, et al. Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. Drugs Context. 2021;10:2020-8-7. doi:10.7573/dic.2020-8-7.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
